Background: Accumulating evidence suggests that the immune system may be an important target for new treatment approaches in schizophrenia. Positron emission tomography (PET) and radioligands binding to the translocator protein (TSPO), which is expressed in glial cells in brain including immune cells, represents a potential method for patient stratification and treatment monitoring. This study examined if patients with first episode psychosis and schizophrenia had altered TSPO levels as compared to healthy control subjects. Methods: PubMed was searched for studies comparing patients with psychosis to healthy controls using second-generation TSPO radioligands. The outcome measure was distribution volume (V T ), an index of TSPO levels, in frontal cortex (FC), temporal cortex (TC) and hippocampus (HIP). Bayes factors (BF) were applied to examine the relative support for higher, lower or no-change of TSPO levels in patients as compared to healthy controls. Results: Five studies, with 75 patients with first-episode psychosis or schizophrenia and 77 healthy control subjects were included. BF showed strong support for lower patient V T relative to no-change (all BF>32) or relative to an increase (all BF>422) in all brain regions. From the posterior distributions, mean patient-control differences in standardized V T values were -0.48 for FC (95% credible interval (CredInt)=-0.88 to -0.09), -0.47 for TC (CredInt=-0.87 to -0.07) and -0.63 for HIP (CredInt=-1.00 to -0.25). Discussion: The observed reduction of TPSO in patients may correspond to altered function or lower density of brain immune cells. Future studies should focus on investigating the underlying biological mechanisms and their relevance for treatment.
Introduction
Genetic, epidemiological and biomolecular data suggest that the immune system is involved in the pathophysiology of schizophrenia (1) (2) (3) . When translating these findings into clinical trials, initial studies have shown positive effect of medication targeting the immune system when used as addon treatment to antipsychotics (4) (5) (6) . To aid further development of this therapeutic approach, tools for directly assessing the status of the brain immune system are needed to allow for patient stratification and monitoring of treatment effects.
Using Positron Emission Tomography (PET), the localization and activation state of central nervous system (CNS) immune response modulators can be assessed with radioligands targeting the glial cell marker 18 kDa translocator protein (TSPO) (7) (8) (9) . During the last decade, a handful of TSPO PET studies have been performed in patients with early-stage psychosis or manifest schizophrenia, showing inconclusive results. Early reports using the first-generation TSPO radioligand (R)-[ 11 C]PK11195 showed increased binding in small patient groups (n=7 and n=10) (10, 11) , albeit with outcome measures that show low accuracy and reliability (i.e. binding potential estimated from rate constants) (12) (13) (14) . More recent studies in larger samples using the same radioligand, but without blood sampling for full quantification, did not replicate these findings (15) (16) (17) .
Concerns regarding the low signal to noise ratio of (R)-[ 11 C]PK11195 sparked the development of a series of second-generation TSPO radioligands, showing much greater specific binding (18) (19) (20) (21) .
These tools have subsequently been used to revisit the question of TSPO increases in psychosis (22) (23) (24) (25) (26) . When employing gold standard outcome measures of binding in the absence of a reference region (distribution volume, V T , obtained using kinetic modeling with metabolite-corrected arterial plasma as input function), no increases have thus far been found in patients. In some cases, trend-level (24) or significantly lower TSPO levels (23) were shown.
All previous TSPO PET studies in psychosis have been performed with relatively small sample sizes. In addition, TSPO radioligands display a substantial within-and between-subject variability (12, 27) , even after accounting for the TSPO rs6971 polymorphism which is known to affect radioligand binding in vivo (28) (29) (30) . This has important implications for sensitivity and the power to detect differences between psychotic patients and controls. Indeed, the power to detect an expected significant medium-sized difference between diagnostic groups (at alpha=0.05) has ranged from 23% to 34% in previous designs (22) (23) (24) (25) (26) . Medication status has also differed both between and within these studies. Since antipsychotics have been shown to dampen the immune response, this further limits the conclusions that can be drawn (31) . Here, we sought to overcome these limitations and clarify the use of TSPO PET as a biomarker of immune dysfunction in schizophrenia. We conducted an individual participant data (IPD) meta-analysis of all TPSO PET studies performed in psychosis or schizophrenia using second-generation radioligands, where V T was included as the outcome measure. The primary objective was to evaluate the hypotheses of 1) an increase or 2) a decrease or 3) no difference in V T between patients and healthy control subjects.
A secondary objective was to assess the effects of antipsychotic medication on TSPO binding.
Materials and Methods

PRISMA, pre-registration and code availability
This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses of Individual Participant Data (PRISMA-IPD) (32) and according to a study specific pre-registration protocol. The pre-registration protocol and all code used in this study can be found on the public repository https://github.com/pontusps/TSPO_psychosis.
Selection Criteria and Search Strategy
We set out to obtain individual participant data from all PET studies that 1) used a second-generation TSPO radioligand, 2) reported distribution volume (V T ) values in the CNS in patients with psychosis as compared to healthy controls (HC), and 3) reported TSPO affinity type of all participants. To our knowledge there are currently five published studies reporting such data, using the radioligands [ 11 C]PBR28, [ 18 F]FEPPA and [ 11 C]DPA713 (22) (23) (24) (25) (26) . In order to ascertain that no relevant studies were omitted from this meta-analysis, we performed a systematic literature search on PubMed. Only articles published after 2004 were included in the search, corresponding to the year when the first report on a second-generation TSPO radioligand was published (33) . Search terms included, among others: "psychotic disorder", "schizophrenia", "positron emission tomography", "translocator protein 18 kDa" and "peripheral benzodiazepine receptor" (for full list of search terms see Supplementary Information 1). All TSPO PET studies in psychosis or schizophre-nia which were not included are listed in supplementary Table 1 , along with a detailed explanation of the selection criteria. Corresponding authors of eligible studies were contacted via email and all agreed to contribute.
Requested data
Requested IPD included V T values from the Frontal Cortex (FC), Temporal Cortex (TC) and Hippocampus (HIP) regions of interest (ROIs), patient-control status, TSPO genotype, age, sex and medication status, Positive And Negative-Syndrome Scale in Schizophrenia (PANSS) scores (or equivalent) and duration of illness. These three ROIs were selected since four out of five included studies had reported V T from all of them. Upon request, the corresponding author of the remaining study (22) , provided unpublished IPD from all three ROIs to allow for consistent pooling.
In order to account for range differences between different radioligands used across studies, we z-scored all ROI V T values within each genotype group of each study.
Quality control
The first author (PPS) examined the integrity of the obtained IPD datasets. The data was checked for outliers and inconsistencies to the published data (such as number of participants, means, ranges, and SDs of V T and age), which were then resolved following discussion with the authors of the relevant study.
Meta-analysis and statistics
The studies included in this meta-analysis recruited participants of two different TSPO affinity types (high-affinity binders, HABs; and mixed-affinity binders, MABs), used different radioligands, and applied different image analysis procedures. In order to estimate the difference in V T between diagnostic groups (∆V T ) while taking this hierarchical structure into account, we constructed and compared four different Bayesian linear mixed effect (BLME) models of increasing complexity: M1) standardized ROI V T was specified as dependent variable, diagnostic group as fixed effect, genotype and study as random effects with varying intercepts; M2) The same as M1 but with varying slopes of the random effect of genotype (i.e. allowing for differences in ∆V T between HABs and MABs); M3) The same as M1 but with varying slopes of the random effect of study (i.e. allowing for differences in ∆V T between studies); M4) The same as M1 but with varying slopes for both random effects (i.e. allowing for differences in ∆V T between genotypes and studies). The model with the best fit to data, as determined by Widely Applicable Information Criterion (WAIC) and Leave-One-Out Cross-validation (LOOC) scores, was selected (34) .
Following model selection, we first examined the hypothesis that patients have higher TSPO binding in the brain (H1). For each ROI we quantified the relative evidence of elevated TSPO expression in patients compared to the null-hypothesis of no change (H0). This was done using order-restricted Bayes Factor (BF) hypothesis testing (35) (36) (37) on ∆V T . BF quantifies the relative evidence, or support, for one hypothesis over another as a ratio of their average likelihoods. A BF > 10 is usually considered as strong evidence in favor of a hypothesis (and, consequently, BF < 0.1 translates into strong evidence of the opposite hypothesis) (35) . We calculated BF H1:H0 to quantify the evidence in favor of an elevated ROI V T signal, compared to no change, in patients. Secondly, we examined whether patients had lower levels of V T in the ROI (H2). Again, this was done by employing an order-restricted BF test of decreased V T in patients (BF H2:H0 ) over no change.
Finally, we calculated the support for H2 over H1 (BF H2:H1 ), signaling how much more likely a decrease in patient TSPO binding is compared to an increase.
For each ROI, H1 and H2 were specified as half-Gaussian (normal) distributions centered on zero with a standard deviation of 0.5. Hence, in order to perform order-restricted hypothesis testing of patient-control differences, the priors over ROI ∆V T were specified as half-Gaussians (SD=0.5) with a lower bound of zero for H1, and an upper bound of zero for H2. The Savage-Dickey Ratio method was then used to calculate BFs. The standard deviation was set a-priori to 0.5 as this assigns high plausibility to ∆V T values ranging from 0 to a medium-sized difference (38, 39) . A medium-sized difference was considered a reasonable prediction, based on the precision of the outcome measure (27) .
A robustness check of the effect of different prior widths on BF was performed by varying the SDs of the half-Gaussian distributions (SD = 0.2 and 0.8 -corresponding to an expected small and large effect size of ∆V T , respectively) when testing all hypotheses. For the prior on the SDs of the random effects, half-Cauchy distributions (with a scale of 0.707) were used. These weakly informative priors were chosen as the numbers of genotype groups (n=2) and studies (n=5) are small (40) .
We also estimated the overall effect size of standardized V T difference between patients and HC. This was done using model M3 with a non-truncated, weakly regularizing prior (Gaussian with a SD of 10) over the fixed effect. M3 was selected since it also allowed us to extract the study specific effects of ROI ∆V T (random slopes), and the corresponding SD of these effects (τ).
Using these we produced a "forest plot" of ROI ∆V T and examined τ as a measure of studyheterogeneity, in line with the PRISMA-IPD guidelines.
For the secondary aim of analyzing medication effects on V T , we added an additional predictor, denoting medication status, to the best fitting BLME model. This predictor quantifies the additional effect of being medicated, after controlling for patient-control status. For each ROI, the prior distribution over the beta coefficient was a non-truncated Gaussian centered on zero with a SD of 10. The posterior of this predictor was then extracted together with its summary statistics (mean and 95% credible intervals (CredInt95%)) to examine the effect of medication.
We also examined the correlation between ROI V T values and PANSS-Positive, PANSS-Negative scores as well as duration of illness (DOI) using linear effect modelling, allowing the correlations to vary between studies. All data was z-transformed within study (and within genotype for V T ) and a uniform prior, ranging from -1 to 1, was specified for the beta coefficient.
In addition, frequentist equivalents of the best fitting model, showing p-values for patientcontrol differences in standardized V T for each ROI are presented in Supplementary Table 2 . The Hamiltonian Markov Chain Monte Carlo sampler STAN (41) , and the R-packages brms (42) and lme4 (43) were used for the statistical modeling in this meta-analysis.
Results
Study selection and data collection
The PubMed search was performed on the 20th of February 2017 and resulted in thirteen research articles. The articles were read in full by two authors (PPS and SC). Both authors concluded independently that five studies (22) (23) (24) (25) (26) fulfilled the inclusion criteria for this meta-analysis (see PRISMA-flowchart in Supplementary Information 2). Each corresponding author provided anonymized individual participant V T values from the frontal cortex (three studies (22) (23) (24) ), dorsolateral prefrontal cortex (DLPFC) (two studies (25, 26) ), temporal cortex (all studies) and hip-pocampus (all studies). For all subsequent analyses in this study, the V T values from FC and DLPFC were considered to represent the same ROI. Characteristics of studies and quality control Table 1 shows (24) . and The mean age of all patients was 33.88 (SD=12.57) and the mean age of healthy controls was 35.42 (SD=15.12) . This corresponds to a negligible difference in age between diagnostic groups (Cohen's d=0.11). Fisher's exact test indicated some skewness in gender distribution between the patient and control groups (p=0.0504). In order to ascertain that any potential differences in ROI V T values between diagnostic groups in the main analysis were not driven by gender differences, we included gender as a covariate, and executed an additional set of BLME models, using the same procedure as outlined in the methods.
Model selection
Model M1 showed a slightly better fit, determined by WAIC and LOOC scores, compared to M2 and M3 ( Table 2) . We therefore used model M1 to obtain order-restricted posterior distributions of ROI ∆V T and subsequently quantified evidence in favor of H0, H1 and H2.
Patient and control difference in V T (primary aim)
BFH1:H0 in favor of elevated V T in patients (H1) were 0.08 for FC, 0.08 for TC and 0.06 for hippocampus. This translates into strong support for the null-hypotheses of no change (H0) relative to an increase in patients. BF H2:H0 in favor of decreased V T in patients (H2) were 32.5 for FC, 34.2 for TC and 1481.0 for hippocampus, compared to H0. This signifies very strong evidence for a lower V T in patients. As a result, there was extremely strong support for H2 over H1 (BF H2:H1 FC: 422.9; TC: 440.6; hippocampus: 24524.0). Hence, a decreased V T in psychosis patients, as compared to healthy controls, is over 422 times more likely than an increased V T , conditioned on the data and the models (see Table 3 and Supplementary Figure 1 for all computed BFs).
When varying the widths (SD=0.2 and SD=0.8) of the Gaussian prior distribution on the fixed effect of differences between patients and controls, there was still strong support in favor of H2 for all ROIs (all BF H2:H0 >15, see Supplementary Table 3 ). The addition of gender as a covariate did not change the qualitative inference for any of the ROIs (all BF H2:H0 >16, see Supplementary Table   4 ). 
Estimation of effect sizes and study heterogeneity
For estimation of effect sizes and study heterogeneity, model M3, with an uninformative prior over ∆V T , was used. Figure 2 displays forest plots of the estimated patient-control difference in each study for each ROI. It also shows the posterior distributions of the standardized ∆V T across all studies, together with summary statistics (mean and credible intervals). The mean of each ROI's posterior distribution corresponds to a medium-sized difference in V T between patients and controls.
For all ROIs, the SDs of the random slopes of studies (τ) were very small (posterior modes<0.04; posterior means<0.22,) and I 2 <15%, signifying low study heterogeneity in ∆V T differences (see Supplementary Figure 2 ).
Effect of medication (secondary aim)
We examined the effect of medication on V T , by adding medication-status as an additional predictor to model M1. For all ROIs, the models showed little to no evidence of a medication effect, allocating as much probability to an increase as to a decrease. The mean of the posterior over the change in standardized V T due to medication was 0.009 for FC (CredInt95% -0.384 to 0.401), -0.013 for TC (CredInt95% -0.407 to 0.381) and -0.040 for HIP (CredInt95% -0.423 to 0.343), see Figure 3 .
Thus, no support was found for a difference between drug-free and medicated patients.
Correlation to PANSS and DOI
There was little to no evidence for a correlation between regional V T and PANSS-Positive scores (posterior means=0.02 to 0.06, p=0.61 to 0.86) as well as between regional V T and PANSS-Negative scores (posterior means=0.02 to 0.05; p=0.71 to 0.88). See Supplementary Figure 4 and Supplemen- Figure 2 : Standardized difference in TSPO binding (estimated using V T ) between patients with psychosis disorder and healthy controls. The posterior distribution for each study-specific ∆V T estimate (random slopes) from the linear mixed model are presented. The black circle denotes the posterior mean, and the thick line the 95% credible interval, which are also presented in text next to the plots. The cross denotes the patient-control mean difference in raw data (together with its 95% CI), without performing linear mixed effects modeling. Hence, the difference between the dot and the cross displays the model shrinkage towards the mean. The overall ∆V T estimate shows a clear decrease in patients' TSPO binding, compared to healthy controls.
tary Table 5 for full reporting of V T and PANSS correlations. There was little to no evidence for a correlation between regional V T and DOI (posterior means = -0.11 to -0.07; p = 0.28 to 0.52). See Supplementary Figure 5 and Supplementary Table 6 for full reporting of V T and DOI correlations.
Discussion
The main finding of this IPD meta-analysis was a reduction in binding of the glial cell marker TSPO in schizophrenia and first-episode psychosis compared to healthy control subjects. Using Bayesian linear-mixed-effect modeling, we observed very strong evidence of lower TSPO binding, measured using V T , in the FC, TC and hippocampus, contrary to the hypothesis of elevated TSPO in patients. As such, this study constitutes the most conclusive in vivo investigation of TSPO in psychosis to date.
Antipsychotic medication has been shown to attenuate blood cytokine levels in patients (31) as well as inhibit immune cell activity in vitro (45) . Although the effect on TSPO expression in animals is less conclusive (46) , these observations suggest that TSPO binding could be lower in Figure 3 : Posterior distributions over the differences in standardized brain TSPO binding (estimated using V T ) values between patients and controls, and the additional effect of medication status (being medicated with anti-psychotics or not at the time of PET). The posterior distributions of medication effect are centred on zero and suggest that anti-psychotic treatment does not affect brain V T , after differences between psychosis patients and controls have been accounted for. medicated compared to unmedicated subjects. However, our secondary analysis of the effect of medication status yielded no evidence for such a difference in TSPO binding between drug-free and medicated patients. This indicates that the observed reduction is not an effect of exposure to antipsychotic treatment.
A wealth of data have demonstrated increases in pro-inflammatory markers, such as cytokines, in CSF and plasma in patients across disease stages of schizophrenia (3, 47) . In the brain, these signaling molecules are mainly released by microglia and astrocytes, which have key roles in the immune response (9) . Therefore, increases in numbers or activity of these cells in schizophrenia has been hypothesized (48, 49) . In post-mortem studies, increases in brain glial cell markers such as HLA-DR and CD11b have been observed in patients, although results have been mixed (50) (51) (52) .
With regard to astrocyte markers, there is no evidence of any overall differences between patients and controls (51, 52) . In the case of TSPO, which is expressed in microglia and astrocytes (8, 9, 53) , autoradiographic studies have reported both higher (28) and lower (54) binding in patients as compared to healthy controls. Important caveats, when interpreting these studies, are that the age of patients and control subjects is generally high, and in patients the cause of death is often suicide (52) . A recent translational study examined TSPO in an infection-mediated animal model of schizophrenia. Increases in pro-inflammatory cytokines were found in brain regions which also showed reductions in TSPO levels as measured using immunohistochemistry (55) , an observation that paralleled TSPO PET and CSF data in patients (24) . Importantly, microglia and astrocytes have been found to exist in both pro-and anti-inflammatory states (56, 57) , which cannot be differentiated by TSPO. Indeed, very recent in vitro data suggest that M1 (pro-inflammatory) macrophages may show reduced TSPO expression (58) . The above discussed literature, together with the results of our study, challenges the utility of TSPO as an exclusively pro-inflammatory marker in schizophrenia. Lower TSPO binding could indicate a compensatory mechanism to a pro-inflammatory signal (55, 59) , or altered function of glial cells such as abnormal energy utilization (60) . Since stimulation of TSPO has shown to attenuate microglial activation in response to neuroinflammatory challenges (61-63), lower TSPO in psychosis could also indicate an inherent weaker anti-inflammatory response. These hypotheses all need to be addressed in future studies.
Since there is no brain region devoid of TSPO expression (64, 65) , metabolite-corrected arterial plasma measurements of radioligand concentration are necessary for accurate in vivo quantifica-tion of binding. In order to overcome variability that may be associated with the arterial measurements (27, 66) , relative measures of binding, such as distribution volume ratios (DVRs), have been proposed (22) . Out of the studies included in this meta-analysis, one reported a significant elevation of DVR in schizophrenia patients and people at clinical risk for psychosis (22) whereas three studies showed no difference in schizophrenia (23) (24) (25) . More recently, no increase in DVR was found in high risk individuals (67) . We chose not to include DVR in our analysis. The interpretation of patient-control differences obtained by dividing binding in a target region with that of a reference region are complicated by the possibility that there could be alterations in specific binding in the reference region as well. In addition, the reliability of DVR for TSPO radioligands has been found to be low (68) . Given the lack of a true reference region, V T is the most suitable outcome for TSPO quantification, but it is not without drawbacks. Apart from glial specific binding (V S ), the signal includes non-specific and free radioligand (V ND ). A general caveat with all studies performed using V T is that, without blocking data (69) , it cannot be excluded that V ND differs between groups. However, for TSPO imaging, this has yet to be shown for any disorder or condition. Also, TSPO binding is expressed in perivascular and endothelial cells (55, 70) , and under certain conditions also neurons (71) . Further research is needed to evaluate the contribution of these components to observed decrease in V T in schizophrenia. Finally, although arterial measurement currently represents the most accurate estimate available of radioligand delivery to brain, it cannot be fully excluded that unknown factors affecting the accuracy of these measures could be unequally distributed between groups. Of the included studies, only Bloomfield et al. (22) , reported changes in input function (increases, as shown in an ensuing publication (72)), whereas Collste et al. (23) and Hafizi et al. (25) found no group differences.
In this IPD meta-analysis, the hierarchal statistical models allowed us to investigate the difference in TSPO binding between patients with psychosis and healthy controls across five different studies. By including only studies employing second-generation radiotracers, and reporting the standard outcome measure V T , the analysis fulfils the pre-condition of meta-analytical models that outcomes should stem from the same underlying distribution of effects. Synthesizing data in this way, we were able to overcome the critical limitation of small sample sizes in the individual reports. Despite this, the total number of included subjects did not allow for investigations of specific subgroups, such as different disease stages.
Conclusions
The present study shows that TSPO binding is reduced across several brain regions in patients with first-episode psychosis and schizophrenia, suggesting an altered function, or reduced density of immune and glial cells. Further work is needed to assess the exact biological meaning of these changes, using both clinical and translational studies. of interest in relation to the work described.
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